PSA Levels and Biopsy Samples After Implant Radiation and Hormone Therapy in Patients With Stage I or Stage II Prostate Cancer
PSA Levels and Biopsy Samples After Implant Radiation and Hormone Therapy in Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Studying samples of blood and tissue from patients with prostate cancer after
 receiving implant radiation therapy and luteinizing hormone-releasing hormone agonist may
 help doctors identify biomarkers related to cancer and help doctors predict how patients will
 respond to treatment.

 PURPOSE: This laboratory study is looking at PSA levels and biopsy samples after undergoing
 implant radiation therapy and luteinizing hormone-releasing hormone agonist therapy in
 patients with stage I or stage II prostate cancer.
OBJECTIVES:

 -  To analyze biopsy results at 36 months after permanent iodine I 125 implantation therapy
 and luteinizing hormone-releasing hormone (LHRH) agonist therapy for patients with
 untreated intermediate-risk prostate cancer.

 OUTLINE: Patients received luteinizing hormone releasing-hormone (LHRH) agonist therapy and
 permanent iodine I 125 implantation on protocol JUSMH-BRI-GU05-01.

 Patients undergo blood sample collection and tissue biopsy for biomarker/laboratory analysis
 at 36 months after receiving brachytherapy and releasing-hormone agonist therapy. PSA levels
 and biopsy results are compared.
DISEASE CHARACTERISTICS:

 -  Histologically or cytologically confirmed prostate cancer

 -  Previously untreated disease prior to participation on protocol JUSMH-BRI-GU05-01

 -  Intermediate-risk disease as defined by the following:

 -  Clinical stage < T2c

 -  Prostate-specific antigen (PSA) ≤ 20 ng/mL

 -  Gleason score < 8

 -  Previously enrolled on protocol JUSMH-BRI-GU05-01

 PATIENT CHARACTERISTICS:

 -  ECOG performance status 0-1

 -  Life expectancy ≥ 3 months

 -  WBC ≥ 2,000/μL

 -  Hemoglobin ≥ 10.0 g/dL

 -  Platelet count ≥ 100,000/μL

 -  Serum creatine level ≤ 2.0 mg/dL

 -  ALT and AST ≤ 100 IU/L

 -  No other cancer requiring treatment

 -  No poorly controlled hypertension (i.e., diastolic blood pressure ≥ 120 mm Hg)

 -  No severe psychiatric disorders, including schizophrenia or dementia

 -  No poorly controlled diabetes

 -  Considered appropriate for study participation, as determined by the Principal
 Investigator or Clinical Investigator

 PRIOR CONCURRENT THERAPY:

 -  No prior drugs for benign prostatic hyperplasia (other than antiandrogen therapy)

 -  No prior surgery for prostate cancer

 -  No concurrent steroid drugs (except for ointment)

 -  No other concurrent antiandrogen therapy